Blueprint Medicines is partnering with Roche to develop and market a cancer drug near approval for use in patients with tumors that test positive for a specific genetic mutation.
The drug at the center of the deal is a pill called pralsetinib, created and developed by the Cambridge, Mass-based biotech to target solid tumors with alterations to a gene called RET. Blueprint has already submitted pralsetinib to the Food and Drug Administration and European regulators seeking approval to treat patients with RET-driven, non-small cell lung cancer.
Under a separate application, the FDA could accelerate an expanded use of the drug to include patients with a type of thyroid cancer.
About the Author Reprints
